Drug Trial Radar · NCT03158311
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
Last checked: Nov 19, 2026Latest source record: Oct 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,426
Actual
Start
Feb 5, 2018
Primary completion
Jul 12, 2019
Study completion Jul 19, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium in uncontrolled moderate to severe asthmatic patients. The planned duration of treatment in this study was 24 weeks, followed up by a 7-day follow-up period.
Conditions
- Asthma
Interventions
QVM149Drug
Indacaterol acetate / glycopyrronium bromide / mometasone furoate
Salmeterol/fluticasone plus tiotropiumDrug
Free triple arm of salmeterol / fluticasone plus tiotropium
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total ScoreTime frame: Baseline and Week 24
Locations
163 sites in 20 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Bahía Blanca, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Ciudad Autonoma de Bs As, Argentina
Novartis Investigative Site
Mendoza, Argentina
Novartis Investigative Site
Mendoza, Argentina
Novartis Investigative Site
Mendoza, Argentina
Novartis Investigative Site
Salta, Argentina
Novartis Investigative Site
Santa Fe, Argentina
Novartis Investigative Site
Berazategui, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Florida, Buenos Aires, Argentina
Novartis Investigative Site
Lanus, Buenos Aires, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Novartis Investigative Site
Nueve de Julio, Buenos Aires, Argentina
Novartis Investigative Site
Ranelagh, Partido de Berazate, Buenos Aires, Argentina
Novartis Investigative Site
Concepción del Uruguay, Entre Ríos Province, Argentina
Novartis Investigative Site
Santa Rosa, La Pampa Province, Argentina
Novartis Investigative Site
Buenos Aires, Nueve De Julio, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Tucumán Province, Argentina
Novartis Investigative Site
Curicó, Maule Region, Chile
Novartis Investigative Site
Santiago, Santiago Metropolitan, Chile
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Bogota, Cundinamarca, Colombia
Novartis Investigative Site
Lovosice, Czechia
Novartis Investigative Site
Miroslav, Czechia
Novartis Investigative Site
Teplice, CZE, Czechia
Novartis Investigative Site
Ostrava Poruba, Czech Republic, Czechia
Novartis Investigative Site
Prague, Czech Republic, Czechia
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.